| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1996;62:798-809
© 1996 The Society of Thoracic Surgeons
Thoracic Service, Departments of Surgery, Pathology, and Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
Background. The terms large cell and mixed small-large cell neuroendocrine carcinoma (LCNC, MNC) have been proposed to describe distinct types of high-grade neuroendocrine lung tumors. However, cytologic appearance and neuroendocrine immunohistochemical stains cannot uniformly distinguish these from other neuroendocrine tumors, such as typical and atypical carcinoids or small cell carcinoma, or nonendocrine lung cancers such as large cell undifferentiated carcinoma. This study sought to determine the patterns of expression in LCNC and MNC of several molecular markers often abnormally expressed in lung cancers.
Methods. Primary lung tumors with neuroendocrine features operated on between 1984 and 1994 were reviewed and classified as typical carcinoid (TC), atypical carcinoid (AC), LCNC, MNC, and small cell lung cancer (SCLC) based on mitotic rate, extent of necrosis, and cytoarchitectural features. Immunohistochemistry was performed using antibodies MIB-1 for Ki67, pAb1801 for p53, OP-66 for Rb, 31G7 for EGFR. Staining was scored as 0 to 4+ (0 = less than 5%, 1+ = 5% to 20%, 2+ = 20% to 50%, 3+ = 50% to 80%, 4+ = more than 80%) for p53, Ki67, and EGFR; and negative, focal, or positive for Rb. Overall survival was calculated by the Kaplan-Meier method and prognostic factors compared by log rank test.
Results. Ninety-two tumors were examined: 25 TC, 7 AC, 24 LCNC, 18 MNC, 18 SCLC. The LCNC and MNC presented more frequently as stage II or III tumors (n = 28, 66%) than TC and AC (n = 5, 15%). Median survival for LCNC and MNC was 18.7 months, for SCLC 14.3 months, and has not been reached for TC and AC tumors. TC and AC tumors were uniformly characterized by low proliferative rate, absent p53, and normal Rb staining. LCNC, MNC, and SCLC showed a high proliferative rate, abnormal p53, and absent Rb staining. Overexpression of EGFR was frequent in all five tumor types.
Conclusions. (1) Ki67, p53, and Rb help distinguish LCNC and MNC from TC and AC. (2) Small numbers of patients preclude comparison of survival rates, but LCNC/MNC have a median survival similar to comparable early stage SCLC, and clearly worse than TC/AC. These results justify a sharp separation of high-grade neuroendocrine tumors from carcinoids, and suggest a close relationship between LCNC, MNC, and SCLC.
This article has been cited by other articles:
|
|
 |
|
  M. Rugge, M. Fassan, R. Clemente, G. Rizzardi, L. Giacomelli, G. Pennelli, C. Mescoli, D. Segat, and F. Rea Bronchopulmonary Carcinoid: Phenotype and Long-term Outcome in a Single-Institution Series of Italian Patients Clin. Cancer Res., January 1, 2008; 14(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iyoda, K. Hiroshima, Y. Nakatani, and T. Fujisawa Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujiwara, I. Sekine, K. Tsuta, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, K. Yamada, and T. Tamura Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung Jpn. J. Clin. Oncol., July 24, 2007; (2007) hym053v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Battafarano, F. G. Fernandez, J. Ritter, B. F. Meyers, T. J. Guthrie, J. D. Cooper, and G. A. Patterson Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, Y. Moriya, T. Mizobuchi, M. Otsuji, Y. Sekine, K. Shibuya, T. Iizasa, Y. Saitoh, and T. Fujisawa Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity Ann. Thorac. Surg., June 1, 2004; 77(6): 1891 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Paci, A. Cavazza, V. Annessi, I. Putrino, G. Ferrari, S. De Franco, and G. Sgarbi Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study Ann. Thorac. Surg., April 1, 2004; 77(4): 1163 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hage, A. B. de la Riviere, C.A. Seldenrijk, and J.M. M. van den Bosch Update in Pulmonary Carcinoid Tumors: A Review Article Ann. Surg. Oncol., July 1, 2003; 10(6): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zacharias, A. G. Nicholson, G. P. Ladas, and P. Goldstraw Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection Ann. Thorac. Surg., February 1, 2003; 75(2): 348 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, M. Baba, Y. Saitoh, H. Ohwada, and T. Fujisawa Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors Ann. Thorac. Surg., April 1, 2002; 73(4): 1049 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lonardo, V. Rusch, J. Langenfeld, E. Dmitrovsky, and D. S. Klimstra Overexpression of Cyclins D1 and E Is Frequent in Bronchial Preneoplasia and Precedes Squamous Cell Carcinoma Development Cancer Res., May 1, 1999; 59(10): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
